Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Gore
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Related publications
A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Journal of Health Economics and Outcomes Research
VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Annals of Hematology
Medicine
Hematology
Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin
British Journal of Haematology
Hematology
Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Early Data From a Phase Ii Trial of Pembrolizumab (Pem) and Entinostat (Ent) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (Hl) and Follicular Lymphoma (Fl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology